CI Global Health Sciences Corporate Class

Series F USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date August 2000
CAD Total net assets ($CAD)
As at 2026-09-30
$248.7 million
NAVPS
As at 2026-11-03
$31.7169
MER (%)
As at 2026-03-31
1.24
Management fee (%) 0.90
Units outstanding
As at
-
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.5033

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

F 324
A ISC 301
DSC SO* 401
LL SO 1401
P 90324
*No new purchases directly into switch only funds.

Performance2 As at 2026-10-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
4.76% -1.82% 4.14% 14.85% 18.84% 4.48% 1.27% 3.44% 7.12%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.5033
2021-03-26 0.1714
2020-12-18 0.2724
2020-09-25 0.2584
2020-06-26 0.1886
Payable date Total
2020-03-20 0.4395
2019-12-13 0.2744
2019-09-27 0.3063
2019-06-21 0.2883
2019-03-22 0.4530

Management team

First we'll display the Team Company and then the Team members
Matthew Strauss

CI Global Health Sciences Corporate Class

Series F USD
 
Portfolio allocations4 As at 2026-09-30
Asset allocation (%)
  • US Equity 80.67
  • International Equity 17.29
  • Canadian Corporate Bonds 2.44
  • Other -0.01
  • Cash and Equivalents -0.39
Sector allocation (%)
  • Healthcare 93.79
  • Exchange Traded Fund 3.66
  • Fixed Income 2.44
  • Other 0.50
  • Cash and Cash Equivalent -0.39
Geographic allocation(%)
  • United States 80.16
  • Switzerland 7.07
  • United Kingdom 6.31
  • Netherlands 3.93
  • Canada 1.39
  • Europe 0.63
  • Other 0.50
  • Denmark 0.01
Top holdings6
Sector (%)
1. Eli Lilly and Co Drugs 9.50%
2. Johnson & Johnson Drugs 8.06%
3. AbbVie Inc Drugs 7.08%
4. Thermo Fisher Scientific Inc Healthcare Equipment 6.38%
5. AstraZeneca PLC Drugs 6.31%
6. UnitedHealth Group Inc Healthcare Services 6.20%
7. Abbott Laboratories Healthcare Equipment 5.18%
8. Stryker Corp Healthcare Equipment 4.90%
9. Merck & Co Inc Drugs 4.83%
10. Danaher Corp Healthcare Equipment 4.74%
11. DexCom Inc Healthcare Equipment 4.47%
12. argenx SE Drugs 3.93%
13. SPDR S&P Biotech ETF (XBI) Exchange Traded Fund 3.66%
14. Vertex Pharmaceuticals Inc Drugs 3.43%
15. Novartis AG Cl N Drugs 3.26%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.